These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36512326)

  • 1. Salidroside ameliorates pathological cardiac hypertrophy via TLR4-TAK1-dependent signaling.
    Guo Z; Liu FY; Yang D; Wang MY; Li CF; Tang N; Ma SQ; An P; Yang Z; Tang QZ
    Phytother Res; 2023 May; 37(5):1839-1849. PubMed ID: 36512326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed lineage kinase-3 prevents cardiac dysfunction and structural remodeling with pressure overload.
    Calamaras TD; Baumgartner RA; Aronovitz MJ; McLaughlin AL; Tam K; Richards DA; Cooper CW; Li N; Baur WE; Qiao X; Wang GR; Davis RJ; Kapur NK; Karas RH; Blanton RM
    Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H145-H159. PubMed ID: 30362822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ubiquitin-specific protease 19 blunts pathological cardiac hypertrophy via inhibition of the TAK1-dependent pathway.
    Miao R; Lu Y; He X; Liu X; Chen Z; Wang J
    J Cell Mol Med; 2020 Sep; 24(18):10946-10957. PubMed ID: 32798288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myricetin Alleviates Pathological Cardiac Hypertrophy via TRAF6/TAK1/MAPK and Nrf2 Signaling Pathway.
    Liao HH; Zhang N; Meng YY; Feng H; Yang JJ; Li WJ; Chen S; Wu HM; Deng W; Tang QZ
    Oxid Med Cell Longev; 2019; 2019():6304058. PubMed ID: 31885808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMEM100 acts as a TAK1 receptor that prevents pathological cardiac hypertrophy progression.
    Zhang BB; Zhao YL; Lu YY; Shen JH; Li HY; Zhang HX; Yu XY; Zhang WC; Li G; Han ZY; Guo S; Zhang XT
    Cell Commun Signal; 2024 Sep; 22(1):438. PubMed ID: 39261825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialyltransferase7A promotes angiotensin II-induced cardiomyocyte hypertrophy via HIF-1α-TAK1 signalling pathway.
    Yan X; Zhao R; Feng X; Mu J; Li Y; Chen Y; Li C; Yao Q; Cai L; Jin L; Han C; Zhang D
    Cardiovasc Res; 2020 Jan; 116(1):114-126. PubMed ID: 30854566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1q-tumour necrosis factor-related protein-3 exacerbates cardiac hypertrophy in mice.
    Ma ZG; Yuan YP; Zhang X; Xu SC; Kong CY; Song P; Li N; Tang QZ
    Cardiovasc Res; 2019 May; 115(6):1067-1077. PubMed ID: 30407523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olmesartan ameliorates pressure overload-induced cardiac remodeling through inhibition of TAK1/p38 signaling in mice.
    Wu L; Mei L; Chong L; Huang Y; Li Y; Chu M; Yang X
    Life Sci; 2016 Jan; 145():121-6. PubMed ID: 26706286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GCN5-mediated regulation of pathological cardiac hypertrophy via activation of the TAK1-JNK/p38 signaling pathway.
    Li J; Yan C; Wang Y; Chen C; Yu H; Liu D; Huang K; Han Y
    Cell Death Dis; 2022 Apr; 13(4):421. PubMed ID: 35490166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tripartite Motif 8 Contributes to Pathological Cardiac Hypertrophy Through Enhancing Transforming Growth Factor β-Activated Kinase 1-Dependent Signaling Pathways.
    Chen L; Huang J; Ji YX; Mei F; Wang PX; Deng KQ; Jiang X; Ma G; Li H
    Hypertension; 2017 Feb; 69(2):249-258. PubMed ID: 27956576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of TRADD attenuates pressure overload-induced cardiac hypertrophy through regulating TAK1/P38 MAPK signalling in mice.
    Wu L; Cao Z; Ji L; Mei L; Jin Q; Zeng J; Lin J; Chu M; Li L; Yang X
    Biochem Biophys Res Commun; 2017 Feb; 483(2):810-815. PubMed ID: 28013046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TBC1D25 Regulates Cardiac Remodeling Through TAK1 Signaling Pathway.
    Guo S; Liu Y; Gao L; Xiao F; Shen J; Xing S; Yang F; Zhang W; Shi Q; Li Y; Zhao L
    Int J Biol Sci; 2020; 16(8):1335-1348. PubMed ID: 32210723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling.
    Xu L; Su Y; Yang X; Bai X; Wang Y; Zhuo C; Meng Z
    Phytomedicine; 2023 Jun; 114():154779. PubMed ID: 37023527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FBXW5 acts as a negative regulator of pathological cardiac hypertrophy by decreasing the TAK1 signaling to pro-hypertrophic members of the MAPK signaling pathway.
    Hui X; Hu F; Liu J; Li C; Yang Y; Shu S; Liu P; Wang F; Li S
    J Mol Cell Cardiol; 2021 Feb; 151():31-43. PubMed ID: 32971071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II-induced cardiomyocyte hypertrophy in vitro is TAK1-dependent and Smad2/3-independent.
    Watkins SJ; Borthwick GM; Oakenfull R; Robson A; Arthur HM
    Hypertens Res; 2012 Apr; 35(4):393-8. PubMed ID: 22072105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tabersonine attenuates Angiotensin II-induced cardiac remodeling and dysfunction through targeting TAK1 and inhibiting TAK1-mediated cardiac inflammation.
    Dai C; Luo W; Chen Y; Shen S; Wang Z; Chen R; Wang J; Chattipakorn N; Huang W; Liang G
    Phytomedicine; 2022 Aug; 103():154238. PubMed ID: 35696800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RNF207 exacerbates pathological cardiac hypertrophy via post-translational modification of TAB1.
    Yuan L; Bu S; Du M; Wang Y; Ju C; Huang D; Xu W; Tan X; Liang M; Deng S; Yang L; Huang K
    Cardiovasc Res; 2023 Mar; 119(1):183-194. PubMed ID: 35352799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Specificity Phosphatase 26 Protects Against Cardiac Hypertrophy Through TAK1.
    Zhao J; Jiang X; Liu J; Ye P; Jiang L; Chen M; Xia J
    J Am Heart Assoc; 2021 Feb; 10(4):e014311. PubMed ID: 33522247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 6-Gingerol protects against cardiac remodeling by inhibiting the p38 mitogen-activated protein kinase pathway.
    Ma SQ; Guo Z; Liu FY; Hasan SG; Yang D; Tang N; An P; Wang MY; Wu HM; Yang Z; Fan D; Tang QZ
    Acta Pharmacol Sin; 2021 Oct; 42(10):1575-1586. PubMed ID: 33462378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-specificity phosphatase 14 protects the heart from aortic banding-induced cardiac hypertrophy and dysfunction through inactivation of TAK1-P38MAPK/-JNK1/2 signaling pathway.
    Li CY; Zhou Q; Yang LC; Chen YH; Hou JW; Guo K; Wang YP; Li YG
    Basic Res Cardiol; 2016 Mar; 111(2):19. PubMed ID: 26891723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.